Skip to content

Study · Measured the body's own peptide · 1996

2 results

Expression of vasoactive intestinal peptide, substance P and bombesin-flanking peptide in nasal polyps.

Kühn AG, Arnold W

ORL; journal for oto-rhino-laryngology and its related specialties1 Jul 1996Cited by 4 (Europe PMC)

PMID8883111 (opens in a new tab)DOI10.1159/000276842 (opens in a new tab)PepBankPUB-08883111
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with nasal polyps, immunohistological expression of VIP did not differ from normal nasal mucosa.

    In plain wordsIn people with nasal polyps, the body's own VIP was found in the same places and amounts as in normal nasal lining.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP expression in nasal polyps versus normal nasal mucosa
    Study

    n = 30

    Comparator
    Normal nasal mucosa
    Outcome group
    Endogenous peptide levels · Respiratory

    Source sentences

    Summary
    Comparing localization and intensity of the immunohistological reaction in nasal mucosa and nasal polyp tissue, there was no difference in the expression of the three neuroendocrine substances.
    3 context sentences
    Summary · context
    The results indicate that VIP, SP and BFP have an equal distribution in nasal polyps and normal nasal mucosa.
    Summary · context
    The aim of this study was to compare immunohistologically the presence and distribution of substance P (SP), vasoactive intestinal peptide (VIP) and bombesin-flanking peptide (BFP) in normal nasal mucosa and nasal polyps.
    Summary · context
    The expression was studied using Formalin-fixed and paraffin-embedded biopsy sections from 20 patients with nasal polyps and 10 controls with normal nasal mucosa from the anterior part of the inferior turbinate.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with nasal polyps, expression of VIP did not differ between allergic and nonallergic subjects.

    In plain wordsIn people with nasal polyps, the body's own VIP showed no difference between allergic and nonallergic patients.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP expression in allergic versus nonallergic polyp patients
    Study

    n = 20

    Comparator
    Nonallergic subjects
    Outcome group
    Endogenous peptide levels · Respiratory

    Source sentences

    Summary
    There was no difference of expression in the polyposis group itself concerning allergic and nonallergic subjects.
    2 context sentences
    Summary · context
    The aim of this study was to compare immunohistologically the presence and distribution of substance P (SP), vasoactive intestinal peptide (VIP) and bombesin-flanking peptide (BFP) in normal nasal mucosa and nasal polyps.
    Summary · context
    The expression was studied using Formalin-fixed and paraffin-embedded biopsy sections from 20 patients with nasal polyps and 10 controls with normal nasal mucosa from the anterior part of the inferior turbinate.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.